On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The completion of this study could positively impact Pfizer and BioNTech’s stock performance, as successful results may lead to new vaccine offerings, enhancing their market position. This development ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.